论文部分内容阅读
目的探讨胺碘酮治疗充血性心力衰竭(CHF)并室性心律失常的临床疗效及安全性。方法将62例CHF并室性心律失常患者随机分为治疗组及对照组,对照组给予常规抗心力衰竭治疗,治疗组在对照组的基础上加以应用胺碘酮治疗,对比分析两组患者在抗室性心律失常、左室射血分数、心脏性猝死、心力衰竭再住院率、药物不良反应等方面的情况。结果治疗组在抗室性心动过速(VT)、心脏性猝死、人均再住院次数、左室射血分数(LVEF)等各方面均明显优于对照组,差异有统计学意义(P<0.05)。结论在积极治疗心力衰竭且把握好剂量的基础上,胺碘酮对心力衰竭室性心律失常具有较好的疗效,是一种安全的抗心律失常药。
Objective To investigate the clinical efficacy and safety of amiodarone in the treatment of congestive heart failure (CHF) and ventricular arrhythmia. Methods Sixty-two patients with CHF and ventricular arrhythmia were randomly divided into treatment group and control group. The control group was given conventional anti-heart failure treatment. The treatment group was treated with amiodarone on the basis of the control group. Anti-ventricular arrhythmia, left ventricular ejection fraction, sudden cardiac death, re-hospitalization rate of heart failure, adverse drug reactions and so on. Results The treatment group was significantly better than the control group in the aspects of anti-ventricular tachycardia (VT), sudden cardiac death, rehospitalization per capita, and left ventricular ejection fraction (LVEF), the difference was statistically significant (P <0.05 ). Conclusions Amiodarone has a good effect on ventricular arrhythmia in heart failure and is a safe antiarrhythmic drug on the basis of active treatment of heart failure and good dosage.